These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 3428460)

  • 21. Interleukin-6 and its surrogate C-reactive protein are useful serum markers for monitoring metastasized malignant melanoma.
    Deichmann M; Benner A; Waldmann V; Bock M; Jäckel A; Näher H
    J Exp Clin Cancer Res; 2000 Sep; 19(3):301-7. PubMed ID: 11144523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low plasma coenzyme Q10 levels as an independent prognostic factor for melanoma progression.
    Rusciani L; Proietti I; Rusciani A; Paradisi A; Sbordoni G; Alfano C; Panunzi S; De Gaetano A; Lippa S
    J Am Acad Dermatol; 2006 Feb; 54(2):234-41. PubMed ID: 16443053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta- carotene, lycopene, alpha-tocopherol, and selenium.
    Breslow RA; Alberg AJ; Helzlsouer KJ; Bush TL; Norkus EP; Morris JS; Spate VE; Comstock GW
    Cancer Epidemiol Biomarkers Prev; 1995 Dec; 4(8):837-42. PubMed ID: 8634654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [S-100B and MIA (melanoma inhibiting activity) serum proteins: a prospective study of their value as melanoma progression markers].
    Dornier C; Dousset B; Legras B; Barbaud A; Schmutz JL
    Ann Dermatol Venereol; 2002 May; 129(5 Pt 1):739-40. PubMed ID: 12124520
    [No Abstract]   [Full Text] [Related]  

  • 25. [Tumor markers in melanoma].
    Morsches B; Prellwitz W; Benes P; Schramm P; Trumpfheller R; Korting GW
    Dermatol Monatsschr; 1984; 170(6):380-90. PubMed ID: 6205909
    [No Abstract]   [Full Text] [Related]  

  • 26. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors.
    Proebstle TM; Jiang W; Högel J; Keilholz U; Weber L; Voit C
    Br J Cancer; 2000 Jan; 82(1):118-23. PubMed ID: 10638977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma.
    Visús C; Andres R; Mayordomo JI; Martinez-Lorenzo MJ; Murillo L; Sáez-Gutiérrez B; Diestre C; Marcos I; Astier P; Godino J; Carapeto-Marquez de Prado FJ; Larrad L; Tres A
    Melanoma Res; 2007 Apr; 17(2):83-9. PubMed ID: 17496783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Intestinal protein-losing syndrome in malignant melanoma with gastrointestinal tract involvement].
    Goebell H; Dombrowski H; Schmitz-Moormann P; Martini GA
    Internist (Berl); 1970 Apr; 11(4):142-5. PubMed ID: 4933144
    [No Abstract]   [Full Text] [Related]  

  • 29. Metastatic melanoma.
    Wong KF
    Br J Haematol; 2006 Sep; 134(6):554. PubMed ID: 16787494
    [No Abstract]   [Full Text] [Related]  

  • 30. Prognostic value of serum VEGF in melanoma patients: a pilot study.
    Ascierto PA; Leonardi E; Ottaiano A; Napolitano M; Scala S; Castello G
    Anticancer Res; 2004; 24(6):4255-8. PubMed ID: 15736481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating adiponectin levels in relation to melanoma: a case-control study.
    Mantzoros CS; Trakatelli M; Gogas H; Dessypris N; Stratigos A; Chrousos GP; Petridou ET
    Eur J Cancer; 2007 Jun; 43(9):1430-6. PubMed ID: 17512191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of the determination of serum markers in patients with malignant melanoma.
    Lugović L; Situm M; Buljan M; Poduje S; Sebetić K
    Coll Antropol; 2007 Jan; 31 Suppl 1():7-11. PubMed ID: 17469741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [In vitro study of peripheral blood with thymidine-3H in the diagnosis of melanoma of the skin].
    Tolkacheva EN; Savvateeva ZhP; Agranat VZ
    Med Radiol (Mosk); 1976 Dec; 21(12):25-9. PubMed ID: 1025413
    [No Abstract]   [Full Text] [Related]  

  • 34. Detection of circulating tumor lysate-reactive CD4+ T cells in melanoma patients.
    Ladekarl M; Agger R; Fleischer CC; Hokland M; Hulgaard EF; Kirkin A; von der Maase H; Petersen MS; Rytter C; Zeuthen J; Gundersen HJ
    Cancer Immunol Immunother; 2004 Jun; 53(6):560-6. PubMed ID: 14985861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of tyrosinase mRNA by an optimised nested RT-PCR in the peripheral blood of patients with advanced malignant melanoma.
    Glumac N; Hocevar M; Snoj M; Novakovic S
    J Exp Clin Cancer Res; 2001 Dec; 20(4):529-36. PubMed ID: 11876547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A defined region of loss of heterozygosity at 11q23 in cutaneous malignant melanoma.
    Herbst RA; Larson A; Weiss J; Cavenee WK; Hampton GM; Arden KC
    Cancer Res; 1995 Jun; 55(12):2494-6. PubMed ID: 7780954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nerve growth factor and malignant melanomas.
    Fabricant RN; Todaro CJ
    N Engl J Med; 1978 Feb; 298(7):402. PubMed ID: 622109
    [No Abstract]   [Full Text] [Related]  

  • 38. Serum sialic acid concentrations in malignant melanoma.
    Ryan AH; Fennelly JJ
    Eur J Cancer Clin Oncol; 1981 Jul; 17(7):843-4. PubMed ID: 7199476
    [No Abstract]   [Full Text] [Related]  

  • 39. Melanin inclusions in the peripheral blood leukocytes of a patient with malignant melanoma.
    Weil SC; Holt S; Hrisinko MA; Little L; DeBacker N
    Am J Clin Pathol; 1985 Nov; 84(5):679-81. PubMed ID: 4061395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating levels of leukocyte and immune interferon in 34 patients with malignant skin melanoma.
    Grassil R; Fiorini I; Grassi C
    Int J Biol Markers; 1987; 2(3):213-4. PubMed ID: 3131453
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.